43 results on '"Al Hallak, Mohammed Najeeb"'
Search Results
2. RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth
3. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset
4. Interim results of the randomized phase 2 cohort of study FW-2020-01 assessing the efficacy, safety and pharmacodynamics of CM24 in combination with nivolumab and chemotherapy in advanced/metastatic pancreatic cancer.
5. Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC)
6. Targeting KRAS in pancreatic cancer: new drugs on the horizon
7. Gastrointestinal stromal tumor: a review of current and emerging therapies
8. KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?
9. The phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
10. A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.
11. Abstract B117: Phase 1 study of CM24 in combination with nivolumab in patients with advanced pancreatic cancer - Survival, potential biomarker and effect on neutrophil extracellular traps (NETs)
12. Gastric cancer: a comprehensive review of current and future treatment strategies
13. Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
14. The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors
15. S2603 When Cancer Takes a Flight: A Rare Case of Rectal Adenocarcinoma Metastasizing to the Orbit
16. Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers
17. Data from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
18. Supplementary Figures 1-4, Tables 1-2 from Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
19. A phase I study of CPI-613 (devimistat) in combination with chemoradiation in patients with pancreatic adenocarcinoma.
20. S1817 Primary Squamous Cell Biliary Carcinoma With Liver Metastasis Is Rare but Malicious
21. Abstract CT136: Interim safety and efficacy results from a phase 1b study of CM24 in combination with nivolumab in adults with advanced solid tumors
22. Phase Ib study of anetumab ravtansive in combination with immunotherapy or immunotherapy plus chemotherapy in mesothelin-enriched advanced pancreatic adenocarcinoma: NCI10208.
23. Experience with 177Lu-Dotatate in patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NET): Report from a single urban cancer center.
24. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers
25. Preferences and attitudes of cardiologists in the management of cancer patients.
26. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer
27. Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs
28. Exosomal microRNA in Pancreatic Cancer Diagnosis, Prognosis, and Treatment: From Bench to Bedside
29. Molecular profiling of pancreatic neuroendocrine neoplasms (panNENs): A single-institution experience.
30. Prognostic impact of XPO1 mutations in metastatic non-small cell lung cancer (NSCLC).
31. Predictors of early readmission to hospital and mortality in patients with malignant ascites: Analysis of the nationwide readmissions database.
32. A novel inhibitor for KRASG12C mutant lung carcinoma
33. Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth
34. Paraneoplastic leukemoid reaction in a patient with metastatic adenocarcinoma of the lung
35. Comprehensive genomic profiling in metastatic pancreatic adenocarcinoma, correlation with early death versus prolonged survival.
36. Paraneoplastic leukemoid reaction in a patient with metastatic adenocarcinoma of the lung.
37. The Gut Microbiome and Cancer: A Comprehensive Review of Melanoma, Lung, Head and Neck and Gastrointestinal Tumors
38. Pan-tumor survey of RETfusions as detected by next-generation RNA sequencing identified RETfusion positive colorectal carcinoma as a unique molecular subset
39. Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.
40. Regulator of Chromosome Condensation (RCC1) a novel therapeutic target in pancreatic ductal adenocarcinoma drives tumor progression via the c-Myc-RCC1-Ran axis.
41. Primary Squamous Cell Biliary Carcinoma With Liver Metastasis Is Rare but Malicious.
42. Anticancer efficacy of KRASG12C inhibitors is potentiated by PAK4 inhibitor KPT9274 in preclinical models of KRASG12C mutant pancreatic and lung cancers.
43. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.